Steven Chmura to Lung Neoplasms
This is a "connection" page, showing publications Steven Chmura has written about Lung Neoplasms.
Connection Strength
2.837
-
Flipping the Null: Lessons From Breast Cancer and Recalibrating Expectations in Oligometastases. Int J Radiat Oncol Biol Phys. 2022 12 01; 114(5):840-842.
Score: 0.316
-
From Idea to Clinical Practice: A Brief History of Oligometastatic Disease. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):576-580.
Score: 0.314
-
A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
Score: 0.291
-
Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. JAMA Oncol. 2021 Jun 01; 7(6):845-852.
Score: 0.286
-
Putting the "BR" in SBRT. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):13-14.
Score: 0.235
-
Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer? Cancer. 2018 07 15; 124(14):2878-2880.
Score: 0.233
-
Oligometastasis-Directed Ablative Therapy: A Clinical Trial Question. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):448.
Score: 0.213
-
Stereotactic radiotherapy for pulmonary metastases. Semin Thorac Cardiovasc Surg. 2013; 25(4):292-9.
Score: 0.171
-
DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. 2024 Dec; 25(8):e448-e452.
Score: 0.089
-
Should We Target Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy? J Natl Cancer Inst. 2023 06 08; 115(6):605-607.
Score: 0.082
-
Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022 12; 3(12):1498-1512.
Score: 0.079
-
Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):645-654.
Score: 0.077
-
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
Score: 0.073
-
Evaluation of Dose Distribution to Organs-at-Risk in a Prospective Phase 1 Trial of Pembrolizumab and Multisite Stereotactic Body Radiation Therapy (SBRT). Pract Radiat Oncol. 2022 Jan-Feb; 12(1):68-77.
Score: 0.073
-
Radiation treatment planning study to investigate feasibility of delivering Immunotherapy in Combination with Ablative Radiosurgery to Ultra-High DoSes (ICARUS). J Appl Clin Med Phys. 2021 Mar; 22(3):196-206.
Score: 0.070
-
Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases. Pract Radiat Oncol. 2016 Nov - Dec; 6(6):e291-e298.
Score: 0.050
-
The evolving role of radiotherapy in treatment of oligometastatic NSCLC. Expert Rev Anticancer Ther. 2015; 15(12):1459-71.
Score: 0.049
-
Surgery or ablative radiotherapy for breast cancer oligometastases. Am Soc Clin Oncol Educ Book. 2015; e8-15.
Score: 0.046
-
Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012; 7(12):e50141.
Score: 0.040
-
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81.
Score: 0.037
-
Risk of second malignancies in patients with early-stage classical Hodgkin's lymphoma treated in a modern era. Cancer Med. 2015 Apr; 4(4):513-8.
Score: 0.012